Rocal-M.

Rocal-M is a multi-ingredient nutritional supplement used for the prevention and management of calcium, vitamin D, and trace mineral deficiencies. Established/guideline-supported uses include:

• Prevention and treatment of osteoporosis — as an adjunct to lifestyle measures and, where prescribed, anti-osteoporotic therapy (e.g. bisphosphonates), to ensure adequate calcium and vitamin D intake.
• Calcium and vitamin D3 deficiency states, including nutritional rickets and osteomalacia, particularly when dietary intake is insufficient.
• Increased calcium/vitamin D/mineral requirements during pregnancy and lactation, under medical supervision.
• Adjunct supplementation in the elderly, in post-menopausal women, and in individuals with limited sun exposure or malabsorption, to support bone mineralization and reduce fracture risk.
• General nutritional supplementation of calcium, vitamin D3, magnesium, zinc, copper, manganese, and boron when dietary intake is inadequate.

Rocal-M is a supportive/adjunct therapy and does not replace prescribed treatment for diagnosed bone disease.

Each film-coated tablet of Calcium Carbonate + Vitamin D3 + Multimineral typically contains:

• Calcium Carbonate 1250–1500 mg (providing approximately 500–600 mg elemental calcium)
• Vitamin D3 (Cholecalciferol) 200–400 IU
• Magnesium (as magnesium oxide/sulfate)
• Zinc (as zinc oxide/sulfate)
• Copper (as cupric oxide)
• Manganese (as manganese sulfate)
• Boron (as boron citrate)

Exact strengths vary by brand and dosage form (film-coated tablet, effervescent tablet, or chewable tablet); refer to the specific product label for exact composition.

Rocal-M is a fixed-dose combination nutritional supplement formulated to support bone health. Calcium carbonate provides elemental calcium, the principal mineral required for bone mineralization; vitamin D3 (cholecalciferol) enhances intestinal absorption of calcium and supports calcium homeostasis; and the accompanying trace minerals (magnesium, zinc, copper, manganese, and boron) act as cofactors in bone matrix formation and remodeling.

Rocal-M is available in Bangladesh in film-coated and effervescent tablet forms and is commonly used for the prevention and adjunct management of calcium/vitamin D deficiency and bone-related conditions such as osteoporosis.

Rocal-M belongs to the therapeutic class of calcium and vitamin D combination supplements with trace minerals, used in bone metabolism and mineral supplementation.

Calcium Carbonate + Vitamin D3 + Multimineral combines several agents that act together on bone mineral metabolism:

• Calcium carbonate dissociates in the acidic environment of the stomach to release calcium ions, which are absorbed in the small intestine (both via active vitamin D-dependent transport and passive diffusion) and are essential for bone mineralization, neuromuscular function, and cell signalling.
• Vitamin D3 (cholecalciferol) is hydroxylated in the liver and kidney to its active form, calcitriol, which increases intestinal absorption of calcium and phosphate, promotes renal calcium reabsorption, and regulates bone remodeling in conjunction with parathyroid hormone.
• Magnesium, zinc, copper, manganese, and boron serve as essential cofactors for enzymes involved in collagen synthesis, bone matrix formation, and osteoblast/osteoclast activity, supporting overall bone strength.

Together, these components help maintain adequate serum calcium levels and support normal bone density and strength.

Rocal-M film-coated tablets should be swallowed whole with a full glass of water, preferably with or after meals to improve calcium absorption and reduce gastrointestinal discomfort. Effervescent tablets should be fully dissolved in a glass of water before drinking. Doses should not be taken at the same time as tetracycline/fluoroquinolone antibiotics, levothyroxine, bisphosphonates, or iron supplements; separate administration by at least 2–4 hours.

Rocal-M has the following clinically significant interactions:

• Tetracycline and fluoroquinolone antibiotics: Calcium chelates with these antibiotics, forming insoluble complexes that significantly reduce antibiotic absorption and efficacy. Separate dosing by at least 2–4 hours (antibiotic before or well after Rocal-M).
• Levothyroxine: Calcium carbonate can reduce absorption of levothyroxine, potentially causing hypothyroidism to become undertreated. Separate administration by at least 4 hours.
• Bisphosphonates (e.g. alendronate, risedronate): Concurrent calcium significantly reduces bisphosphonate absorption. Bisphosphonates should be taken on an empty stomach, at least 30–60 minutes before Rocal-M or any calcium-containing product.
• Thiazide diuretics: May increase the risk of hypercalcemia when combined with calcium and vitamin D supplements; serum calcium should be monitored.
• Digoxin/digitalis glycosides: Hypercalcemia arising from excessive calcium/vitamin D intake can potentiate cardiac glycoside toxicity and arrhythmias.
• Phenytoin, phenobarbital, and other enzyme-inducing anticonvulsants: May reduce the effectiveness of vitamin D3 by accelerating its metabolism.
• Iron and zinc supplements: Calcium can reduce absorption of oral iron; if co-administered, separate doses by several hours.
• Corticosteroids: May reduce calcium absorption, potentially requiring dose adjustment of Rocal-M.

Rocal-M is generally well tolerated at recommended doses. Reported side effects include:

• Common: Mild gastrointestinal disturbances such as constipation, flatulence, bloating, nausea, and mild abdominal discomfort.
• Less common: Diarrhea, dry mouth, mild skin rash.
• Rare (usually with prolonged excessive intake): Hypercalciuria, hypercalcemia (with symptoms such as fatigue, confusion, loss of appetite, and metallic taste — see Overdose), and, very rarely, milk-alkali syndrome or nephrocalcinosis.

Calcium and vitamin D requirements increase during pregnancy and lactation, and Rocal-M may be used under medical supervision when dietary intake is insufficient. However, Rocal-M should be used only if clearly needed, at doses that do not exceed recommended daily allowances, since excessive vitamin D intake has shown teratogenic effects in animal studies and maternal hypercalcemia has been associated with fetal harm. The potential benefit should justify the potential risk, and a physician should be consulted before use.

Calcium and vitamin D3 are excreted into breast milk; doses within the recommended range are generally considered compatible with breastfeeding, but a physician should be consulted, and excessive maternal intake should be avoided.

Use Rocal-M with caution in the following situations:

• Renal impairment or history of kidney stones: increased risk of hypercalciuria, nephrocalcinosis, and worsening renal function; periodic monitoring of serum and urinary calcium and renal function is recommended with prolonged use.
• Conditions predisposing to hypercalcemia (e.g. sarcoidosis, hyperparathyroidism) — see Contraindications.
• Concomitant use of other calcium, vitamin D, or multivitamin/mineral products — total intake from all sources should be accounted for to avoid exceeding safe upper limits.
• Prolonged immobilization may increase the risk of hypercalcemia in patients also receiving calcium supplementation.
• Timing of other medications — see Interactions for antibiotics, levothyroxine, and bisphosphonates that require dose separation.

Discontinue and seek medical advice if symptoms of hypercalcemia (nausea, vomiting, constipation, confusion, excessive thirst, or frequent urination) develop.

Overdose of Rocal-M can cause hypercalcemia and hypervitaminosis D, with symptoms including nausea, vomiting, loss of appetite, metallic taste, constipation, abdominal pain, excessive thirst, frequent urination, muscle weakness, confusion, and, in severe cases, cardiac arrhythmias or renal impairment. In case of suspected overdose, discontinue the product immediately and seek immediate medical attention or contact a poison control center; do not attempt specific home treatment. Management is generally supportive and may include intravenous fluids and monitoring of serum calcium under medical supervision.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Elderly: Rocal-M is commonly used in the elderly to support bone health and reduce fracture risk; renal function should be periodically assessed given the higher likelihood of age-related renal impairment.

Renal impairment: Use with caution; contraindicated in severe renal failure (see Contraindications). In mild-to-moderate renal impairment, use only under close medical supervision with periodic monitoring of serum calcium, urinary calcium, and renal function.

Hepatic impairment: No specific dose adjustment is established; vitamin D3 activation requires hepatic hydroxylation, so caution and medical supervision are advised in significant hepatic impairment.

Pediatric use: see Pediatric Uses.

Pregnancy and lactation: see Pregnancy and Lactation.

Duration of Rocal-M therapy depends on the indication. For correction of a diagnosed deficiency, treatment is typically continued for several weeks to months until deficiency is corrected, as guided by clinical response and, where available, laboratory monitoring. For long-term bone health maintenance (e.g. in osteoporosis prevention or the elderly), Rocal-M may be used on an ongoing basis under periodic medical review, with regular monitoring of serum and urinary calcium during prolonged use.

Calcium Carbonate + Vitamin D3 + Multimineral is classified under calcium supplements, vitamin D analogues, and multimineral/trace-element supplements used in bone and mineral metabolism.

Calcium Carbonate + Vitamin D3 + Multimineral works through complementary mechanisms: calcium carbonate supplies elemental calcium for absorption and use in bone mineralization and physiological calcium-dependent processes; vitamin D3 is converted to active calcitriol, which upregulates intestinal calcium-binding protein synthesis to enhance calcium absorption and works with parathyroid hormone to maintain calcium homeostasis; and the trace minerals (magnesium, zinc, copper, manganese, boron) act as enzymatic cofactors supporting collagen cross-linking and bone matrix formation, contributing to bone strength and density.

Rocal-M (effervescent tablet form) may be used in children above 3 years of age for calcium/vitamin D supplementation under medical guidance, at a dose of one tablet daily for ages 3–7 years and one to two tablets daily for children above 7 years. Use in children below 3 years is not established, and safety and efficacy of Rocal-M in this age group have not been established; a pediatrician should be consulted for appropriate calcium/vitamin D dosing in infants and young children. Total intake from diet, other supplements, and fortified foods should be considered to avoid exceeding the tolerable upper intake level for the child's age.